The HER2-positive breast cancer cell line SKBR-3, known to be generally sensitive to HER2-targeting TKIs, was used as a positive control and the HER2-negative MCF-7 breast cancer cell line that is insensitive to anti-HER2 drugs as a negative control [16, 17]. This evidence concerns the gene ERBB2 and breast carcinoma.